Biocom @Biocom

The conversation has shifted from AI companies to AI-enabled companies. Across Biocom's membership, organizations are integrating AI into drug discovery, clinical development, manufacturing and more. In his latest LifeLines article, Miguel Motta, Biocom's senior vice president and COO, and executive director of the San Diego region, explores what comes next for life sciences and AI. Read the article: bit.ly/4eeDGh7

Discover how Biocom’s Group Purchasing programs can scale your hiring strategy. Take our 30-second HR assessment to receive a custom recommendation plan tailored for your company: bit.ly/43KbdLD

Congratulations to our member Synlico Inc., recently named a semifinalist for the Nebius AI Discovery Award. Learn more: bit.ly/4edkT62 Meet their team at #BIO2026 to learn how its SynCausal platform uses patient-derived single-cell data and causal AI to accelerate target discovery and therapeutic development.

Some of the biggest contributors to our industry are not seeking recognition, but they deserve it. Nominate an entrepreneur, scientist, engineer, clinician or community leader under 40 for the #BiocomCatalyst Awards and help shine a light on their impact. Nominate: bit.ly/43M8v7L #BiocomCatalyst

Biocom's Venture Hub Showcase is back for BIO 2026. Join us Monday, June 22 at 10 a.m. for an international pitch event connecting life science innovators with strategic partners and investors shaping the future of the industry. Explore the latest innovations from industry leaders and make the connections that matter. bit.ly/4euxbrP  #BIO2026 #VentureHub

Where is food & agtech capital actually going, and what does current exit activity say about where the market is headed? Join Biocom's Food & AgTech Committee on Friday, June 26 for a webinar breaking down the latest venture capital market data, including where investors are focused and what the current funding environment looks like. Topics include: • How investors are categorizing the agtech landscape • Where capital is concentrating, from AI-enabled precision ag to automation, crop genetics and embedded finance • Exit activity and what it signals for the funding environment • Notable deals, active investors and key company metrics the market is tracking Join us virtually on Friday, June 26, from 11 a.m. – 12 p.m. PDT. Register: bit.ly/4oiufSL

✨ @alliance_socal connects Southern California’s research institutions, business leaders and advisors to bridge gaps and accelerate the regional innovation ecosystem. 💊 @asymchem delivers integrated, client-centric CDMO solutions from discovery through commercial manufacturing. 🧠 Coharts builds Bio-Quantum intelligence to model and intervene in complex biological systems for human health. 💼 @Hands_OnLLC strengthens organizations through talent mobility, leadership development and capability‑building learning programs. 🧪 Interfacial Consultants develops disruptive advanced materials and manufacturing platforms to help innovators incubate next‑generation products. 🩺 @VerseaHealth delivers personalized, proactive and preventive healthcare through rapid diagnostics, ophthalmic solutions and precision medicine discovery.

Women's health innovators, investors, clinicians and health care leaders are invited to join our member, @Startup3Valley, for an exclusive discussion on the future of women's health innovation. This curated event will explore how community-based clinical trials, health economics, investment and regional collaboration can help accelerate the development and adoption of new solutions in women's health. Learn more and request to attend: bit.ly/4x8skUD

Congratulations to our member Pictor on an impressive first year in Carlsbad. Since opening its U.S. headquarters, the company has secured strategic partnerships, expanded its Carlsbad campus with a BSL-2 equipped lab, published three peer-reviewed studies, closed a $5 million pre-Series A round and advanced its targeted proteomics platform across the life science industry. We're proud to have Pictor as part of the Biocom community and look forward to seeing what's next.

Attention Bay Area: Don’t miss our life science happy hour at The Hangar in South San Francisco on June 11. Register today: bit.ly/4dliPID

This week in Greater Los Angeles life sciences: @CapsidaBio will present preclinical data on next-generation ocular capsids at ASGCT; @Endologix acquired Pounce Thrombectomy System; @ImmunityBio received FDA acceptance of a supplemental BLA for ANKTIVA with BCG in bladder cancer; @ReflowMedical shared six-month DEEPER CORONARY results. Subscribe: bit.ly/3WFbOLh

The future of life sciences is being shaped by bold thinkers, innovators and changemakers. Know an entrepreneur, scientist, engineer, clinical expert or community leader under 40 making an impact? Nominate them for the Biocom Catalyst Awards. Nominate today: bit.ly/4ukl3yC

Interested in expanding your clinical development strategy globally? Join our member, MTPConnect, along with the Australian Trade and Investment Commission, for an exclusive seminar exploring Australia's clinical trial ecosystem. June 17 | 2:30 p.m. PDT | Bay Area Register: bit.ly/4dOUnRs June 18 | 3:00 p.m. PDT | Los Angeles Register: bit.ly/3Sledva

📢Registration is now open for our 2026 CEO Summits in San Diego, the Bay Area and Greater LA. Join us to gain valuable insights, participate in critical conversations about the current and future life science landscape, and connect with fellow leaders on a peer-to-peer level. Learn more: bit.ly/4uM7ybT #BiocomCEOSummit #LifeScienceEvents #Biotech

This week in Bay Area life sciences: @Agilent launched the 1290 Infinity III fluorescence detector for UHPLC trace analysis; @AkariTX shared promising preclinical data combining AKTX-101 with KRAS inhibition in pancreatic cancer models; @BioAegis Therapeutics advanced recombinant human plasma gelsolin; @My_Green_Lab opened registration for the International Laboratory Freezer Challenge. Subscribe: bit.ly/40rlR8a

In this month's Regulatory & Reimbursement Newsletter: Biocom submitted comments in response to the FDA’s draft guidance on the use of new approach methodologies in drug development, Kyle Diamantas will serve as acting FDA commissioner following Dr. Makary’s resignation, Michael Davis has been appointed acting director of CDER and more. Read it here: bit.ly/4v7W8zz

It's #NewMemberMonday! 🔬 Ablytx develops drugs that degrade disease-driving proteins on cell surfaces. 🌱 Caffree uses enzymes to convert caffeine into theobromine while preserving flavor and sustainability. 🫀 @Cyclarity Therapeutics develops therapies that target toxic cholesterol to reverse age-related diseases. 💻 Engine Biosciences combines AI and high-throughput biology to accelerate drug discovery and cellular reprogramming. 🩺 @REVClinicalCRO partners with emerging and mid‑size biopharma companies to deliver fast, flexible and capital‑efficient global clinical trials. 🧬 Vivere Oncotherapies engineers next generation gene therapy delivery systems to unlock immunotherapy for hard-to-treat solid tumors.

Catch the most recent Group Purchasing Newsletter to learn more about @centrexIT's new website, @FedEx's AI-powered partnership with ServiceNow, @SharpBusinessUS's zero-waste-toner solution, and @ThermoFisher's new integrated therapy manufacturing platform, partner news and more. Read the full edition: bit.ly/4t9fjqH